Telix Pharmaceuticals Limited

A recent paper published in Theranostics highlights positive results from a pre-clinical collaboration between Telix and Radboud University Medical Center (Radboudumc). Simone Kleinendorst and colleagues evaluated Telix’s investigational carbonic anhydrase IX (CAIX) targeting therapy, TLX250 (177Lu-girentuximab), in combination with two immune checkpoint inhibitors (ICI) for advanced clear cell renal cell carcinoma. The study found that TLX250 combined with ICI showed superior therapeutic outcomes and significantly altered the tumour microenvironment. Based on these results, TLX250 + ICI combination therapy is currently being investigated in the Phase II STARLITE-1 and 2 studies to validate the concept in humans. We recently sat down with one of the publication’s authors and Telix Director of ImmunoOncology Research, Kwame Twumasi-Boateng, to discuss the study and potential future directions for this novel therapy combination. Read the full paper on our Medical channel below, and visit our website for more on Telix’s CAIX-targeting theranostic portfolio: https://lnkd.in/g5jXyZbS

Congratulations to our friends at Mercy Radiology in New Zealand as they begin to image patients with Illuccix® on their brand-new mobile PET-CT unit - the first of its kind in the Southern Hemisphere! The availability of mobile PSMA-PET with Telix’s Illuccix® kit and a gallium generator marks a pivotal step towards ensuring broader access to advanced prostate cancer imaging in New Zealand’s underserved communities. Thanks to Mercy Radiology and Mobile Health Group for helping bridge the gap in prostate cancer care, so that local patients can receive timely and accurate diagnoses, no matter who or where they are. Mobile Imaging | Remy Lim | Jessica Fagan

Telix today issues a revenue and business update for the quarter ended 30 June 2024. Unaudited total revenue grew to US$124M, an increase of 55% on the prior corresponding quarter, primarily driven by U.S sales of Illuccix®. Accordingly, Telix has upgraded its revenue guidance for FY 2024. Key operational highlights include positive data from our prostate cancer therapy programs, TLX591 and TLX592, and significant advancements in our precision medicine portfolio with regulatory filings being progressed for new prostate, kidney and brain cancer imaging agents. For more details on our Q2 2024 results, visit: https://bit.ly/3Y69TRq

Telix welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for how radiopharmaceuticals are reimbursed in the U.S. Refinements to the Hospital Outpatient Prospective Payment System (OPPS) rule would support more equitable and reliable access to advanced imaging for all patients by facilitating continued access after transitional pass-through payment status expires. This would apply to Illuccix® and other new diagnostic products being developed by Telix, if approved. Visit our website for more: https://lnkd.in/gKiUFVh8

For Professor Jeff Dunn AO, President of the Union for International Cancer Control (UICC), new technologies are critical in delivering cancer care in remote and underserved areas, in order to reduce inequities. Telix is proud to be working with patient advocates like Prof. Dunn, to close the gap in prostate cancer care by developing technologies that can help deliver advanced imaging to those who need it, no matter the location, or zip code.

️Happy #PrideMonth! 🌈 Throughout June, we stand united to celebrate and honour those who are creating a more equitable and accepting world for all. Telix is dedicated to ensuring that our people and the patients we serve always feel safe, respected, and valued for who they are.

Thank you for joining Telix at SNMMI 2024 in Toronto, Canada. The world's largest nuclear medicine and molecular imaging event again offered an unparalleled opportunity to connect with patient advocates, physicians and industry in our field. A special thanks to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for convening such a high quality meeting, and to all our global collaborators and friends for the support and commitment to improving patient outcomes. #SNMMI24

Today is World Kidney Cancer Day and the theme for this year is "listening“, highlighting the crucial role of shared decision-making in patient care. Planning and input into Telix's kidney cancer portfolio is vital to ensure we deliver products that address an unmet need. Through patient advisory boards with leading global kidney cancer advocates at the ASCO Genitourinary Cancers Symposium (ASCO GU) in January and the Annual European Association of Urology Congress (EAU) in April, we worked together to identify gaps in the patient pathway from diagnosis to treatment. Together, let's listen, empower, and make a difference. International Kidney Cancer Coalition (IKCC) #WorldKidneyCancerDay24

Telix's ZIRDAC-JP study of TLX250-CDx - our investigational PET imaging agent for kidney cancer - has been published in the Japanese Journal of Clinical Oncology.   These first peer-reviewed results confirm comparability of the dosing and pharmacology of TLX250-CDx between Japanese, and European and American patient populations.   Data from the ZIRDAC-JP study will inform Telix's regulatory strategy for TLX250-CDx (Zircaix®) in Japan, including potential bridging to the Company's successful Phase III ZIRCON Study.   Telix recently announced the completion of its Biologics License Application submission for TLX250-CDx in the United States. TLX250-CDx has not received a marketing authorisation in any jurisdiction. Zircaix brand name is subject to final regulatory approval.

Michael Crosby knows firsthand the impact that prostate cancer can have on the Veteran community. As a Veteran, prostate cancer survivor and patient advocate, Mike fought and beat the disease and is now fighting for other Veterans to receive equitable care. Telix is proud to be working with patient organisations, such as Veterans Prostate Cancer Awareness, to close the gap in prostate cancer care and help deliver equitable access to advanced imaging for all men. Learn more about the great work of VPCa at: www.vpca.vet